Post-Stroke Cognitive Impairment: A Review Focusing on Molecular Biomarkers

• Published in: Journal of molecular neuroscience Vol. 70; no. 8; pp. 1244 - 1254
• Main Authors: Zhang, Xinxin, Bi, Xia
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.08.2020; Springer Nature B.V
• Subjects: Biomarkers; Biomedical and Life Sciences; Biomedicine; Blood circulation; Body fluids; C-reactive protein; Cell Biology; Cerebrospinal fluid; Cognitive ability; Complications; Dementia disorders; Diagnosis; Impairment; Interleukin 10; Interleukin 6; Neurochemistry; Neurology; Neurosciences; Prognosis; Proteomics; Stroke; Biomarkers; Post-stroke cognitive impairment (PSCI); Inflammation; Oxidative damage
• ISSN: 0895-8696; 1559-1166; 1559-1166
• DOI: 10.1007/s12031-020-01533-8

Post-stroke cognitive impairment (PSCI), as one of the major complications after stroke, refers to a series of syndromes from mild cognitive impairment to dementia caused by stroke. Stroke has been reported to increase the risk of cognitive impairment by at least five to eight times. The assessment of PSCI usually relies on neuropsychological tests, but the results of these tests are subjective and inaccurate, and can be insufficient for the diagnosis and prognosis of PSCI. In recent years, an increasing number studies have indicated that changes in the expression of biomarkers such as C-reactive protein (CRP), interleukin 6 (IL-6) and IL-10 in blood, urine and other body fluids are associated with cognitive decline after stroke. Therefore, the detection of biomarkers in circulating blood serum, plasma and cerebrospinal fluid (CSF) may improve the accuracy of diagnosis and prognosis in PSCI. This review aims to summarize the studies on potential molecular biomarkers of PSCI.